Calypso Biotech is a leader in the development of Interleukin15 (IL-15) targeted therapies, currently targeting patients with Celiac Disease and Eosinophilic Esophagitis. They partnered with Rivia in 2022. Below is an extract from an interview with their Chief Medical Officer Dr. Jos Houbiers.
"The problems Rivia is solving are many in regards to review of patient data. It's combining databases into one view so you don't need to go around to all databases. Not only is it a good view of all data in one place, it shows the alignment in time of the different events."
"The Rivia software is actually saving me time, and that's of course, very important. It also allows me to better understand the data because they are integrated and in one view. Combining safety, efficacy, and timing of dosing is really helpful."
"Rivia stands out because of the well designed views of the data. The software really works always very well. The company is quick in answering questions and understanding the needs of customers, and they are willing to adapt."
"Benefiting from Rivia will be the medics in the company because they can easily view the safety data and combine it with dosing and efficacy data. But also clinical leaders could benefit because they can check data quality and progress."
"Try it yourself, and see how it helps. Compare it to other software. I have a lot of experience with other software, and I can tell you the Rivia software sticks out. On top of that, there is the adaptability of the company and the willingness to change things quickly for your specific needs."
"I think every medic in the clinical trial, and also clinical leads in trials, should use this kind of software to have a better overview of their data."
Meet the Biotechs using Rivia who consistently unlock discoveries and accelerate trials.